Facile air oxidation of the conjugate base of rofecoxib (Vioxx™), a possible contributor to chronic human toxicity

被引：25

作者：

Reddy, LR ^{[1
]}

Corey, EJ ^{[1
]}

机构：

[1] Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA

来源：

TETRAHEDRON LETTERS | 2005年 / 46卷 / 06期

关键词：

COX-2; inhibitor; rofecoxib; Vioxx; autoxidation; toxicity;

D O I：

10.1016/j.tetlet.2004.12.055

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

The COX-2 inhibitor rofecoxib (Vioxx(TM), 1) ionizes under physiological conditions to an anion that reacts readily with dioxygen to form inter alia the reactive maleic anhydride derivative 6, a potentially toxic compound. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：927 / 929

页数：3

共 19 条

[1] Role of prostacyclin in the cardiovascular response to thromboxane A2 [J].

Cheng, Y ;

Austin, SC ;

Rocca, B ;

Koller, BH ;

Coffman, TM ;

Grosser, T ;

Lawson, JA ;

FitzGerald, GA .

SCIENCE, 2002, 296 (5567) :539-541

[2] Drug therapy: The coxibs, selective inhibitors of cyclooxygenase-2. [J].

FitzGerald, GA ;

Patrono, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06) :433-442

[3] Coxibs and cardiovascular disease [J].

FitzGerald, GA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (17) :1709-1711

[4]

GAUTHIER J, 2001, CHEM BR AUG, P31

[5]

*GD SEARLE RES LAB, UNPUB

[6]

*GD SEARLE RES LAB, COMMUNICATION

[7] The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects [J].

Halpin, RA ;

Porras, AG ;

Geer, LA ;

Davis, MR ;

Cui, DH ;

Doss, GA ;

Woolf, E ;

Musson, D ;

Matthews, C ;

Mazenko, R ;

Schwartz, JI ;

Lasseter, KC ;

Vyas, KP ;

Baillie, TA .

DRUG METABOLISM AND DISPOSITION, 2002, 30 (06) :684-693

[8] Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2 [J].

McAdam, BF ;

Catella-Lawson, F ;

Mardini, IA ;

Kapoor, S ;

Lawson, JA ;

FitzGerald, GA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) :272-277

[9] Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx™) [J].

Nicoll-Griffith, DA ;

Yergey, JA ;

Trimble, LA ;

Silva, JM ;

Li, C ;

Chauret, N ;

Gauthier, JY ;

Grimm, E ;

Léger, S ;

Roy, P ;

Thérien, M ;

Wang, ZY ;

Prasit, P ;

Zamboni, R ;

Young, RN ;

Brideau, C ;

Chan, CC ;

Mancini, J ;

Riendeau, D .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (23) :2683-2686

[10] Isolation and characterisation of process-related impurities in rofecoxib [J].

Reddy, KVSRK ;

Babu, JM ;

Dubey, PK ;

Sekhar, BC ;

Reddy, GO ;

Vyas, K .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 29 (1-2) :355-360

← 1 2 →